Electrophysiology – Products

Axol Bioscience Ltd, and CENSO Biotechnologies have announced that the two companies have signed a merger agreement. The new entity will be a provider of product and service solutions in the iPSC-based neuroscience, immune cell, and cardiac modeling for drug discovery and screening markets.

Download this app note to learn more about automated patch clamp and the benefits of using it in drug discovery.

Axol Bioscience (Axol), a biotechnology company specializing in the use of stem cell technology, today announced the expansion of its service offering, with the introduction of multi-electrode array (MEA) screening for human induced pluripotent stem cell (hiPSC)-derived cells.

Metrion Biosciences has contributed to two new papers that focus on the application of improved cardiac safety testing protocols and recommendations for best practice for the drug discovery industry.

TTP has established a partnership with NHS Highland and The University of the Highlands and Islands to use clinical data interpretation and machine learning algorithms to predict which patients with atrial fibrillation are able to be successfully treated using electrical cardioversion.

SynapCell and Motac Neuroscience have discovered a new biomarker for monitoring the progression of Parkinson’s disease.

Metrion and LifeArc have announced an extension of their neuroscience-focused ion channel drug discovery collaboration, following the success of the initial twelve-month agreement.

The Ultima 2Pplus enhances multiphoton imaging with a wider field of view, improved sensitivity, broader wavelength range, and flexible sample accommodation.

A major international FDA-led study confirms CellOPTIQ® High Content Assay as leading in vitro platform to assess cardiotoxicity in new drugs.